Skip to main content
Clinical Trials/NL-OMON46509
NL-OMON46509
Recruiting
Not Applicable

Efficacy of MRI-guided Prostate Irreversible Electroporation (IRE) therapy; the EMPIRE-trial. - EMPIRE-trial

Sint Antonius Ziekenhuis0 sites40 target enrollmentStarted: TBDLast updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
40

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following
  • \- Signed written informed consent
  • \- Age \>40 years, and life expectancy of \*10 years.
  • \- Serum PSA \<15ng/mL.
  • \- Histologically proven low\- to intermediate\-risk PCa (i.e. Gleason \*7 with max 3\+4\<\=7\).
  • \- Localized disease (i.e. no extracapsular extension, vesiculae seminalis invasion or suspected metastasis).
  • \- Stage radiological \*T2cN0M0 on mp\-MRI, with \*1 visible and histology proven lesion(s) in the prostate (PI\-RADS 3\-5\). Co\-existing MRI\-unvisible Gleason 6 disease is no exclusion
  • \- Prostatic lesion visible on mp\-MRI, accessible for IRE with a maximum diameter of 20mm in the transversal plane.

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation
  • in this study:
  • \- Patients who are unwilling to sign written informed consent
  • \- Patients with ASA \*4
  • \- Patients with evidence of lesions in contact with the prostatic capsule on mpMRI.
  • \- Patients with evidence of metastatic or nodal disease outside the prostate on mpMRI.
  • \- Patients with GS \>7\.
  • \- Patient with capsular contact of tumour \*6mm in the prostate.
  • \- Patients with previous treatment for PCa.
  • \- Patients with a history of radiotherapy to the pelvis.

Investigators

Similar Trials